Tarsus Q2 2026: XDEMVY Sales Surge 69% to $174M, Operating Cash Flow Turns Positive, and $125M PIPE Priced at $56
TARS sits 44% above its 52-week low of $40.55 on light trading volume (0.4× avg).
Summary
Tarsus reported Q2 2026 XDEMVY net sales of $173.9M (+69% YoY), positive operating cash flow, and a $125M PIPE priced at $56 to fund recent and pending acquisitions.
Key Events · Earnings and Guidance · TARS
-
XDEMVY Sales Surge 69%
Net product sales climbed to $173.9 million in Q2 2026, up from $102.7 million in Q2 2025, as higher prescription volumes and improved gross-to-net discounts took hold.
-
Operating Cash Flow Turns Positive
For the first half of 2026, net cash provided by operating activities reached $36.6 million, a sharp reversal from the $50.0 million use of cash in H1 2025, underscoring robust revenue growth and disciplined working capital management.
-
Strong Liquidity Position
Cash, cash equivalents, and marketable securities stood at $449.7 million as of June 30, 2026, offering ample runway for both operations and strategic initiatives.
-
$125M PIPE Priced at $56.00
On August 5, 2026, a securities purchase agreement was signed for a private placement of 2.1 million shares at $56.00 per share, along with pre-funded warrants, expected to close August 7, 2026, to fund the Alkeus acquisition.
Analysis · TARS · Life Sciences
A standout quarter for Tarsus was fueled by XDEMVY net sales of $173.9 million, a 69% year-over-year leap driven by volume growth and improved gross-to-net yields. The first half of 2026 generated $36.6 million in operating cash flow—a dramatic swing from the $50 million cash burn in the prior-year period. With $449.7 million in cash and investments, the balance sheet remains strong, and the subsequent $125 million PIPE at $56 per share—a modest discount to the current $58.27—provides additional firepower for the recently closed iRenix acquisition and the pending Alkeus deal. The combination of accelerating revenue, cash flow inflection, and a well-supported M&A strategy marks a pivotal quarter.
At the time of this filing, TARS was trading at $58.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $40.55 to $85.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.